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 Manganese (Mn) is an essential dietary element required for several important 
physiological processes.  However, accumulation of Mn due to excessive environmental 
exposure is known to pose neurological health concerns that manifest as movement 
abnormalities and cognitive impairment.  Oxidative stress has been hypothesized to play 
a role in this dysfunction.  In these studies we examined the effect Mn exposure had on 
oxidative stress in the brain with or without antioxidant therapy, and how brain regional 
Mn accumulation affected stereotypic behaviors in rats.  Sprague-Dawley rats raised on 
AIN-93G diet were randomized into a Mn free group (deionized water) and Mn exposed 
group (deionized water with 1 g Mn/L).  Each group was then subdivided into three 
additional groups receiving injections of either saline (vehicle) or antioxidant therapy: 
200 mg/kg N-acetyl-cysteine (NAC) or 5 mg/kg (-)-epigallocatechin-3-gallate (EGCG) to 
yield six groups total, each with an n=6.  During the sixth week of treatment, stereotypic 
rat behaviors (total distance traveled, sleep, sniff, and groom) were monitored using 
Clever Systems Home Cage Scan.  Upon completion of the sixth week the rat brains were 
removed with the caudate putamen (CP) and hippocampus (HC) sectioned out and 
analyzed for Mn and iron (Fe) concentrations, total glutathione (GSH) levels, lipid 
peroxidation in the form of F2-Isoprostanes (F2-IsoPs), along with glutathione peroxidase 
(GPx) and catalase mRNA levels.  Results were considered significant when p≤0.05.  Mn 
exposure significantly increased Mn concentrations in both the CP and HC, accompanied 
by significantly decreased Fe:Mn ratios in Mn-exposed groups.  Mn significantly 
increased total distance traveled in each Mn-exposed group and decreased sniff behavior 
in the Mn only group.  Only modest alterations in GSH and catalase levels were present 
in each region, although, a significant positive correlation between Mn concentration and 
GPx mRNA expression was observed.  Additionally, F2-IsoP results showed no evidence 
of increased oxidative damage compared to CN regardless of EGCG or NAC therapy.  
These data, compared to the body of Mn toxicity research, suggest that oral Mn exposure 
may not generate deleterious levels of oxidative stress leading to overt neurological 
dysfunction.  This exposure paradigm, instead, may result in subtle neurochemical 
alterations associated with behavior change and potential cognitive impairment. 
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CHAPTER I 
INTRODUCTION 
 
 
 Manganese (Mn) is a dietary metal essential for numerous cellular processes 
including macronutrient metabolism, bone growth, cellular free radical defense, and 
ammonia clearance from the brain.  However, excessive exposure t  Mn has been shown 
to result in brain Mn accumulation and subsequent neurotoxicity.  Mn is known to 
accumulate in iron (Fe) rich regions of the brain resulting in neurological symptoms 
associated with movement and behavior abnormalities.  Mn neurotoxicity or 
“Manganism” shares movement disorder symptoms with Parkinson’s disease (PD) and 
initial psychiatric alterations analogous to schizophrenia.  Mn accumulates in the basal 
ganglia, where it has been shown to disrupt neurotransmitter function and damage 
neurons and glial cells, potentially facilitating a neurodegenerative stat . 
 Damage caused by Mn neurotoxicity is hypothesized to result from multiple 
factors.  Mn is known to alter dopamine, γ-aminobutyric acid (GABA) and glutamate 
homeostasis.  A disturbance in these neurotransmitters can propagate movement and 
behavior abnormalities due to modified signal transduction.  Additionally, this may result 
in altered synaptic concentrations of these neurotransmitters disturbing the function of 
glial cells surrounding the synapse.  Indeed, data suggest that Mn alters the ability of 
astrocytes to process synaptic glutamate (the primary excitatory neurotransmitter) 
resulting in over excitation.  Furthermore, Mn indirectly stresses c llular redox status 
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albeit through excitotoxicity, free radical generation, and/or lowering glutathione (GSH) 
levels.  Recent studies have identified a specific species of isoprostanes, F2-Isoprostanes 
(F2-Isops), as a direct biomarker of Mn induced oxidative damage, specifically lipid 
peroxidation.  
 Augmenting cellular redox potential is thought to potentially curb cellular damage 
caused by Mn-induced oxidative stress.  N-Acetyl-Cysteine (NAC) and (-)-
Epigallocatechin-3-gallate (EGCG) are two compounds known to have a sparing affect 
on endogenous antioxidant systems.  NAC is an able cysteine donor to complete the GSH 
tripeptide with glutamate and glycine, ensuring substrate availability for GSH synthesis.  
EGCG has the ability to serve as an antioxidant with eight hydroxl groups available to 
donate electrons, and in vitro studies demonstrate EGCG increased gene expression of 
glutamate-cysteine ligase, which creates the catalytic precursor for de novo GSH 
synthesis.   
 The primary goal of this study is twofold; 1) examine the effect brain Mn 
accumulation has on stereotypic behaviors of rats, 2) examine the effect of Mn on brain 
GSH levels and the overall antioxidant enzyme response, and to explore the effectiveness 
of antioxidant therapy in mitigating cellular damage and modulating GSH levels 
(damaged measured as F2-Isoprostane production).  The specific aims for this study are 
to: 
1. Examine the effect of Mn exposure on behavior by monitoring alterations 
in stereotypic behaviors and relating them to regional brain Mn 
accumulation.  Twenty-one day old Sprague-Dawley rats were exposed to Mn 
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and monitored for changes in behaviors associated with locomotor activity and 
anxiety (total distance traveled, sleep patterns, grooming, and sniffing).   The 
working hypothesis for this aim is that increased Mn levels will lead to changes 
in these behaviors indicative of increased anxiety and disturbed circadian rhythm.  
Furthermore, antioxidant therapy will help normalize disturbances in behavior 
initiated by Mn exposure. 
2. Demonstrate an effect of Mn exposure on glutathione levels and associate 
corresponding changes to endogenous markers of oxidative stress in the rat 
brain. Twenty-one day old Sprague-Dawley rats were used to measure in vivo
GSH levels and F2-Isoprostane formation with or without Mn exposure.  The 
working hypothesis for this aim is that Mn accumulation in the brain will lead to 
altered GSH levels increasing F2-Isoprostane formation, and the addition of 
antioxidant therapy will limit F2-Isoprostane formation by attenuating the 
damage caused by reactive oxygen species.  
 The overall hypothesis of these studies is that Mn exposure indirectly leads to 
neurochemical alterations by disrupting GSH functionality, leaving the brain vulnerable 
to oxidative insult.  The resulting damage may decrease normal neuron and glial cell 
function resulting in altered neurotransmission and manifesting as altered locomotion and 
behavior.  Antioxidant treatment may help mitigate damage caused by oxidative stress 
and help restore normal behavior in Mn exposed rats.  Results from these studies help to 
characterize the role of Mn in the sequelae of neurodegeneration, and may lead to the 
development of possible therapies.  
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
Introduction 
Manganese (Mn) is an essential dietary element that plays a role in the proper 
function of many biological processes including energy metabolism, bone gr wth, blood 
clotting, ammonia clearance and neurotransmitter synthesis in the brain, and cellular free 
radical defense.  Though Mn plays an important biological role, the body necessitates 
minimal amounts to satisfy requirements, with an adequate intake (AI) stablished at 1.8 
or 2.3 mg/day for women and men, respectively (National Academy of Science, 2002).  
Historically, Mn deficiency has not been recognized as a risk to the general public.  Mn 
toxicity, however, has garnished the attention of clinicians and researchers by 
manifesting symptoms similar to Parkinson’s disease (PD).  The onset f Mn toxicity, 
coined “Manganism”, is characterized with anxiety and schizophrenic behavior, followed 
by movement disorders, and impaired memory (Cersosimo and Koller, 2006).  Initial 
cases of Mn toxicity were relegated to occupational exposure, such a  mining or battery 
manufacturing.  Though, emerging cases have identified drinking water as a potential 
source of Mn toxicity (Wasserman et al., 2006).  Regardless of the source, occupational 
exposure to Mn remains the primary culprit of toxicity. Recent attention has focused on 
the anti-knock gas additive methylcyclopentadienyl manganese tricarbonyl (MMT).  
MMT has been used in Canada since 1976, and has recently been approved for us  in the 
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United States (Barceloux 1999).  Unlike acute occupational exposure, widespread use of 
MMT may expose sizeable populations to chronic low doses of aerosol Mn salts (e.g. Mn 
sulfate and Mn phosphate).  These readily inhaled Mn compounds may enter th  body via 
respiration into the lungs or to the brain along the olfactory nerve.  It is unclear how 
chronic low dose exposure will affect exposed populations.  Clinical studies have also 
uncovered formula fed infants and patients receiving total parnenteral ut ition (TPN) as 
populations at risk for Mn toxicity (Hsieh et al., 2007).  Studies have shown infant 
formula to have Mn concentrations 100 times higher than breast milk (Lonnerdal, 1994).  
Lastly, iron deficiency, the most common micro-nutrient deficiency i  the world, can 
promote Mn accumulation within the brain (Erikson et al., 2005a). 
Manganese Exposure 
Dietary 
 Mn is abundant in the food supply with nuts, legumes, vegetables, fruit, and 
brewed tea representing the primary sources followed by red meats and poultry to a lesser 
extent (Aschner and Aschner, 2005).  Currently not enough data have been collcted to 
establish an RDA for Mn intake; however, an AI has been set at 1.8 and 2.3 mg/day for 
adult women and men respectively.  Mn requirements do change throughout the life cycle 
according to growth and developmental needs (Tasker et al., 2004).  The AI for different 
developmental stages is as follows: 3µg/day for <6mo, 600µg for 7-12mo, and 1.2 to 1.5 
mg/day for children 1-3 and 4-8 years, respectively (National Academy of Sciences, 
2002).  The average dietary intake of Mn has been estimated at 2-6 mg/day (Freeland-
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Graves and Turnlund, 1996) with vegetarian diets increasing the amount t 
approximately 11 mg/day (Gibson, 1994).  
 Excess dietary Mn rarely results in toxicity due to tight regulation in the gut.  It is 
estimated that 1-5% of Mn ingested is absorbed (Finley, 2004; Davis et al., 1993).  
Dietary and endogenous factors play a role in this regulation.  One study by Finle  (2004) 
using radio-labeled 54Mn found that men absorb less dietary Mn than women, though 
men retained Mn longer systemically, likely due to plasma ferritin levels.  This finding 
corresponds with duodenal biopsy data that showed divalent metal transporter (DMT-1) 
expression was inversely associated with serum ferritin levels (Zoller et al., 1999).  
DMT-1 is expressed in endothelial cells and serves a transporter f r divalent metal ions 
such as iron (Fe), copper (Cu), Mn, and zinc (Garrick et al., 2003).  Otherfacto s altering 
absorption of Mn, include competition with Fe and other divalent metals for absorption or 
excessive amounts of phytic acid (Aschner and Aschner, 2005; Hurrell, 2004).  Dietary 
Fe deficiency has also been shown to increase intestinal Mn absorption (Finley 1999), as 
well as transport into the brain (Erikson et al., 2005a).  Once in the syst m Mn transport 
in the blood depends on its oxidation state.  Mn2+ travels bound to albumin and gamma-
globulin, where as trivalent Mn3+ readily attaches to unoccupied transferrin (Aschner et 
al., 2007). Mn2+ is the most prevalent species in biological media; however, the mor
cytotoxic free Mn3+ can exist in small quantities.  
Occupational and Environmental Exposure 
 Occupational exposure to Mn is the most common cause of Mn neurotoxicity.  
Several cases of neurotoxicity have been linked to Mn exposure within mining, 
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manufacturing, and welding industries (Hochberg et al., 1996; Crossgrove and Zheng, 
2004).  Inhalation of dense Mn particulate, up to 100-fold higher than established safe 
limits, is not uncommon in workers who display neurological symptoms (Crossgrove and 
Zheng, 2004).  Alternatively, chronic exposure to low dose airborne Mn in the form of 
methylcylopentadienyl manganese tricarbonyl (MMT) may present future health 
concerns, particularity in vulnerable infant and iron deficient populations.  Furthermore, 
Mn toxicity has been linked with contaminated drinking water (Wasserman, 2006; Sahni 
et al., 2007).  In Bangladesh, children drinking from wells with a high Mn content (793 
µg/L, compared to the Environmental Protection Agencies (EPA) established safe limit of 
300 µg/L) had significantly reduced verbal scores and overall intellectual performance 
compared to children consuming water Mn concentrations under the EPA’s established 
safe limit (Wasserman, 2006).  
Transport to the Brain 
 It is well known that Mn accumulates in Fe rich areas of the brain (Erikson et al., 
2002a).  To date several transport mechanism have been discovered, each contributing to 
the transport of Mn into the brain.  The transport mechanism engaged dep nds largely on 
the species of Mn, divalent (Mn2+) or trivalent (Mn3+), and plasma concentrations.  
Entrance of Mn via the cerebral spinal fluid at the choroid plexus tends to favor high 
plasma concentrations, where as cerebral capillary transport at the blood brain barrier 
(BBB) predominate under lower physiologic concentrations (Aschner et al., 2007).  It is 
thought that the majority of Mn is chaperoned into the brain by Mn3+ bound to transferrin 
or uptake of Mn2+ by divalent metal transporter DMT-1 (Aschner et al., 2007).  However, 
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ancillary Mn transport also occurs through active transport, leak pathways, in the form of 
Mn2+ citrate, and through store-operated calcium channels (Aschner and Gan on, 1994; 
Crossgrove et al., 2003; Crossgrove and Yokel, 2005). 
 DMT-1 is a known transporter of Mn and Fe that is expressed on the apical wall 
of endothelial cells, cerebral capillaries, on foot processes of astr cytes (integral to the 
BBB), and choroid epithelia of the blood-CSF barrier (Garrick et al., 2003).  A study by 
Chua and Morgan, (1997) helped characterize the role of DMT-1 in Mn transport using 
homozygous Belgrade (b/b) rats with a defective DMT-1 allele.  Mn and Fe transport into 
the brain was impaired in b/b rats compared to heterozygous (+/b) and Wistar rats 
indicating the importance of DMT-1. 
 Aside from DMT-1, Mn can cross the BBB by a few different mechanisms.  Mn 
complexed with transferrin can bind to transferrin receptors at the cerebral capillaries for 
endocytosis into the capillary endothelium (Fishman et al., 1987).  Within the endothelial 
cell Mn is liberated from systemic transferrin to complex with brain synthesized 
transferrin for transport into the brain.  A small amount of Mn in the blood is bound to 
citrate, this Mn-citrate complex is thought to cross the BBB through monocarboxylate 
transporter (MCT) (Aschner et al., 2007).  Other small scale trnsport mechanisms 
include the zinc family transporter (ZIP) and leak pathways (Aschner et al., 2007).  The 
mechanisms by which Mn travels within the brain are still largely undefined; however, 
transferrin is thought to play a role.   
 Lastly, Mn transport to the brain has also been demonstrated to occur along 
olfactory neurons (Dorman et al., 2002).  Solubility of the Mn species appears to play a 
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role in transport, with more soluble MnCl2 and MnSO4 concentrations peaking rapidly 
compared to less soluble MnHPO4 and insoluble Mn3O4 (Dorman et al., 2001; Dorman et 
al., 2002; Brenneman et al., 2000).  Inhaled Mn concentrates primarily in the olfactory 
bulb, but the mechanism governing Mn relocalization once it has entered the brain has 
yet to be fully elucidated (Leavens et al. 2007). 
 
Figure 2-1.  Manganese Transport at the Blood Brain Barrier – The above figure is a 
schematic of the Mn transport mechanism across the BBB.  Primary transport routes 
(DMT-1 and transferrin endocytosis) are depicted with more abundant BBB density and 
bold arrows compared to the other transport mechanism (ZIP, Mn2+-Citrate, and leak 
pathways).  Endocytosis of Mn-bound transferrin 1) Mn bound to systemic transfe rin 
reaches the BBB. 2) Mn-bound transferrin binds to transferrin receptor. 3) Endocytosis of 
the receptor bound complex 4) Mn is liberated from systemic transferrin and binds to 
brain-produced transferrin where it is transferred across the basolateral surface of the 
capillary endothelium into the brain. 
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Manganese Toxicity 
Systemic 
 Mn toxicity is known to affect multiple organ systems within the body.  The liver 
plays a critical role in Mn homeostasis, accounting for approximately 95% of Mn 
clearance via biliary excretion (Crossgrove and Zheng, 2004).  Hepatic failure poses a 
serious threat to brain and systemic Mn levels.  In fact, decreased liver function due to 
alcoholism, cirrhosis, and hepatitis have been linked to hyper-intensity of T-1 weighted 
MRI’s in human subjects (Malecki et al, 1999).  Liver damage can also result from acute 
Mn exposure, as Mn has been shown to concentrate in the mitochondria of hepatic c lls 
altering Ca2+ levels and electron transport chain (ETC) function (Zhang et al., 2003).  
Altered ATP production may play a critical role in biliary excretion according to a study 
conducted in marine vertebrates that suggests Mn efflux from the liver is influenced by 
an ATP sensitive mechanism (Madejczyk et al., 2009).  Additionally, Mn exposure can 
also affect the kidneys and lungs.  Both ingested (Huang and Lin, 2004) and inhaled 
(Tapin et al., 2006) Mn has been shown to accumulate in the kidneys leading to renal 
failure.  Occupational asthma has also been documented in welders attributed to 
breathing Mn particulate (Beach et al., 1996).  Further investigation in lung epithelial 
cells exposed to Mn revealed increased cytokine production suggesting an flammatory 
response in the lungs due to Mn toxicity (Pascal and Tessier, 2004).  Pulmonary 
absorption of Mn does occur across the alveolar epithelium through non-selective Ca2+ 
channels (Heilig et al., 2006). 
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Neurotoxicity 
 Mn accumulation in the brain, due to overexposure, is centralized in the basal 
ganglia, an area critical to modulating fine-motor skills and a target for the pathology of 
many neurodegenerative diseases.  Similar to Parkinson’s disease, Mn neurotoxicity 
inflicts damage to the globus pallidus and substantia nigra leading to altered dopamine 
levels in the striatum (Cersosimo and Koller, 2006).  The loss of striatal dopamine 
contributes to the symptomatic dysfunction shared by the two disorder. The majority of 
Mn research has focused on perturbations in the nigrostriatal dopaminergic pathway, 
however, it has recently come to light that preceding alterations in γ-aminobutyric acid 
(GABA) and norepinephrine may contribute to dysfunction (Anderson et al., 2008, 2009, 
respectively).   
 Within the brain, excess Mn is primarily sequestered in astrocytes (Aschner et al. 
1999).  Dysfunction is thought to occur when excess Mn burden on astrocytes and other 
glial cells disrupts their ability to modulate the neuronal environment.  This leaves 
neurons vulnerable to excitotoxicity, reactive oxygen species (ROS), and other toxic 
byproducts generally processed by astrocytes.  Astrocytes express a glutamate/aspartate 
transporter (GLAST), clearing extracellular glutamate aftr excitatory neurotransmission 
(Erikson et al., 2002b).  An important function of astrocytes is to recycl  glutamate to 
glutamine by a Mn-dependant astrocyte-exclusive enzyme glutamine synthetase (GS).  
Under normal conditions GS accounts for the majority of Mn in the brain  Glutamate is 
converted to glutamine via GS in the presence of ammonia, released from the astrocyte, 
and taken up by neurons for synthesis of GABA or new glutamate by way of glutamic 
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acid dehydrogenase or glutaminase, respectively (Fitsanakis et al., 2006).  This process 
not only promotes neurotransmitter recycling, but also clears ammonia from the brain by 
using it to form glutamine when condensed with glutamate.  Mn can alter this process as 
evidenced by the use of nuclear magnetic resonance (NMR) spectroscopy in rats after 50 
mg/kg MnCl2 injections, which identified decreased glutamine in the globus pallidus and 
altered glutamate-glutamine-GABA metabolism (Zwingmann et al., 2007).  Additionally, 
in primary astrocyte cell culture 300 µM MnCl2 significantly decreased GLAST mRNA 
expression (Erikson et al., 2002b).  The role that astrocytes play in supporting neurons is 
not exclusive to neurotransmitter metabolism.  Astrocytes also provide neurons with 
cysteine and glycine precursors necessary for neuronal GSH synthe is (Dringen, 2000).  
These data show that astrocyte dysfunction impedes normal neuronal function; therefore, 
it is reasonable to consider astrocytes a target of Mn neurotoxicity. 
 Dysfunction resulting from a Mn toxic environment is ultimately due to Mn 
induced neuronal death.  Whether or not neuronal death is instigated by Mn directly, or 
through Mn-induced neuronal/astrocyte dysfunction has yet to be determined.  
Additionally, the exact mechanisms responsible are by in large undefine .  However, 
multiple hypotheses exist as to how Mn toxicity leads to neurodegeneration. Implications 
of Mn-induced glutamate excitotoxicity, the generation of ROS, and altered energy 
metabolism are commonly thought to be putative mechanisms.  
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Mechanisms of Toxicity 
Excitotoxicity 
 Glutamate, the most abundant excitatory neurotransmitter in the brain can activate 
both ionotropic and metabotropic receptors (Meyer and Quenzer, 2005).  Ionotropic 
receptors such as N-methyl-D-aspartic acid (NMDA) are fast cting ion channels 
allowing Na+ and Ca2+ to enter a cell upon glutamate binding.  Slower acting 
metabotropic receptors function through G-protein linked cell signalling cascades, with 
longer lasting effects.  Excitotoxicity is the result of prolonged activation of both receptor 
species propagating cell death.  Increased intracellular Ca2+, due to excitotoxicity, can 
alter the permeability of the inner mitochondrial membrane diminishig respiration and 
leading to cell death (Hunter and Haworth, 1979; Zoratti and Szabo, 1995). Excess 
intracellular Ca2+ can also disrupt mitochondrial membrane potential initiating apoptosis 
(Lemasters et al., 1987).  Furthermore, a study by Brecht et al. 2001 showed that 
excitotoxicity led to caspase-3 activation and DNA fragmentation in primary neuron-glial 
co-cultures isolated from the hippocampus of mice demonstrating the vuln rability of 
both neurons and glial cells to an excitotoxic assault.   
 Excess synaptic glutamate can result from disturbances in neurotransmitter levels 
causing disregulation of glutamatergic neurons, neuronal death releasing large 
concentrations of neurotransmitters into surrounding synapses, or an inability of 
astrocytes to clear synaptic glutamate.  Mn neurotoxicity may pl y a role in each of these 
scenarios.  
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 As previously mentioned, astrocytes remove glutamate from the synaptic cleft, 
partially due to GLAST function (Aschner 1999; Erikson et al., 2002b).  However, a 
study by Hazell and Norenberg (1997) demonstrated a decrease in glutamate uptake by 
astrocytes exposed to 100 µM MnCl2.  It was unclear if this decrease was due to direct 
inhibition of GLAST or altered Na/K-ATPase function, responsible for establishing ion 
gradients necessary for proper GLAST and glutamate transporter (GLT-1) function (Rose 
et al., 2009).  Concurrent experiments in primary astrocytes exposed t MnCl2 and 
MnSO4 revealed significant decreases in GLAST mRNA levels, corroborating previous 
findings (Erikson et al., 2002b).  In GABAergic AF5 neuronal cells, low level Mn 
treatment increased intracellular and extracellular glutamate by 170% and 198%, 
respectively (Crooks et al., 2007).  Microdialysis experiments show tat Mn spiked 
artificial cerebral spinal fluid decreased synaptic GABA, glutamate, and aspartate levels 
(Takeda et al., 2002).  Alternatively, Mn may lead to increased extracellular GABA in the 
striatum due to decreased GABA transporter (GAT-1) protein expression (Anderson et 
al., 2008).  Likewise, rats injected with 200 µM Mn/kg had significantly increased striatal 
glutamate with amplified cell death (Xu et al., 2009).  This finding supports evidence of 
Mn increased spontaneous glutamate-mediated excitatory postsynaptic potentials 
(EPSPs) in the cortical-striatal glutamate pathway (Centonze, 2001), and increased 
glutamate in the caudate putamen of iron deficient-manganese exposed rats (Erikson et 
al., 2002a).  It has also been suggested that Mn may activate NMDA receptors leading to 
direct over excitation (Spadoni et al., 2000).  Together, these studies establish that altered 
glutamate levels due to Mn toxicity are a putative cause of excitotoxicity and 
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neurodegeneration.  Cell death associated with excitotoxicity may be due to caspase-3 
activation and DNA damage (Brecht et al., 2001), or altered cellular respiration (Zoratti 
et al., 1995).  Additionally, excitotoxicity via kainate administration increases reactive 
oxygen species (ROS) leading to increase hippocampal cell death (Li ng et al., 2000), 
suggesting ROS play a role in excitotoxicity.  
Reactive Oxygen Species 
 The brain is an organ highly susceptible to oxidative stress because of it  high 
energy requirements.  Since glucose is the primary fuel of the brain, the energy demand is 
met through glycolysis and oxidative phosphorylation.  This results in the production of 
superoxide radicals, which are a natural byproduct of oxidative respiration.  Under 
normal conditions superoxide radicals are converted to hydrogen peroxide (H2O2) and O2 
by the superoxide dismutase enzyme family (Cu/Zn-containing SODin the cytosol, or 
Mn-containing superoxide dismutase (MnSOD) in the mitochondia), catalase further 
processes H2O2 into H2O and O2.  However, in the presence of iron, H2O2 is converted to 
the highly reactive hydroxyl radical OH-, by way of the Fenton reaction.  This is 
important with respect to neurodegeneration, as Mn accumulates in Fe rich r gions of the 
brain.  To date it is unclear if Mn can initiate a Fenton like reaction directly; rather, 
evidence suggests that Mn may indirectly cause production of reactive oxyg n species.  
This may be achieved by Mn altering enzymes involved in cellular oxidative defense 
(GSH, catalase, glutathione peroxidase), by decreasing the efficiency of the electron 
transport chain (ETC) leading to increased superoxide production, or by reacting with 
dopamine to produce cytotoxic dopamine quinones.  Dopaminergic cell death is  
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hallmark of Mn toxicity, and evidence suggests that Mn and dopamine have a synergistic 
effect on ROS generation leading to DNA damage and cell death (Oikawa et al., 2006; 
Prabhakaran et al., 2008). 
 Production of free radicals from mitochondrial energy metabolism is a normal 
function of living cells.  Under physiological conditions, these ROS are quenched by 
antioxidant enzymes before deleterious processes can occur.  Normal production of ROS 
has also been recognized to play a role in cell signaling cascade  (Kamata and Hirata, 
1999).  However, the presence of excessive Mn augments ROS production (Ali et al., 
1995), and has been shown to alter mitochondrial membrane potential (Zhang et al., 
2004; Rama Roo and Norenberg, 2004).  Using isolated mitochondria, Zhang et al. 
(2004) demonstrated that 50µM MnCl2 was enough to significantly decrease the function 
of ETC complexes I, II, and III, while 500 µM and 1000 µM MnCl2 significantly 
decreased all four ETC complexes.  These effects were significantly attenuated by 
pretreatment with the antioxidant N-Acetylcysteine (NAC), suggesting ROS generation 
contributed to the damage.  This confirms a previous finding by Bautist  et al. (2000) 
sighting dysfunction in complex I of the ETC, beyond threshold level, of H2O2 induced 
oxidative stress, and suggests that Mn-induced ROS may contribute to mitochondrial 
dysfunction.  Additionally, Mn3+ has been shown to be a more potent inhibitor of 
complex I, compared to the less reactive Mn2+, in cultured PC12 cells (Chen et al., 2001).  
Interference with ETC enzymes leads to increased ROS, specifically superoxide, by 
blocking the normal passage of electrons down the chain to reduce molecular oxygen to 
water (Cassarino and Bennett, 1999).  These studies demonstrate a mechanism by which 
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Mn may lead to altered energy metabolism and mitochondrial dysfunction reating 
increased oxidative stress in the cell. 
 Excessive Mn-induced reactive oxygen species are known to alter several cellular 
processes.  If oxidative damage is apparent in the mitochondria, Ca2+ homeostasis may be 
altered leading to apoptosis (Orrenius, 2007).  A study using primary rat astrocytes by 
Zhaoobao et al. (2008) demonstrated Mn-induced apoptosis via a decrease in inn r-
mitochondrial membrane potential, phosphorylation of the ERK pathway, and activation 
of caspase-3, of which the authors attributed partial cause to ROS.  ROS were also 
implied in ERK and c-Jun N-terminal kinase (JNK) activation of Bax and caspase-3 
proteins, leading to apoptosis in ceramide treated primary mouse astrocytes (Oh et al., 
2006).  Again, these apoptotic pathways are triggered by excessive production of ROS, 
and may be blunted by proper function of antioxidant enzymes, such as GSH, catalase, 
and SOD. 
Manganese role in glutathione biology 
 The tripeptide glutathione (GSH) is one of the most abundant endogenous 
antioxidants, comprising approximately 90% of non-protein thiols in the brain (Anderson 
and Meister, 1983).  Glutathione has the ability to reduce free radicals, in the presence of 
glutathione peroxidase, forming oxidized glutathione (GSSG), which is subsequently 
reduced back to GSH via glutathione reductase.  A strong link has been established 
between GSH and the pathology of neurodegenerative disorders (Schulz et al., 2000 for 
review).  In PD patients, specifically, total GSH levels in the substantia nigra where 40% 
lower than controls, with a modest increase in oxidized GSSG (Sian et al., 1994).   
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 Animal and cell studies have further characterized the role Mn plays in altering 
GSH levels and other markers of oxidative stress.  Inhalation studies utilizing MnSO4 and 
MnPO4 unveiled age, sex, and species related differences on metallothionein (MT) and 
glutamine synthetase (GS), protein and mRNA levels (indirect markers of oxidative 
stress), as well as total GSH (Erikson et al., 2007; Taylor et al., 2006; Weber et al., 2002).  
Monkeys exposed to airborne Mn concentrations ranging from 0.06-1.5 mg Mn/m3 
exhibited a significant decrease in GS protein within the globus pallidus, showed 
decreased MT mRNA expression in the cortex of animals exposed to >0.3 mg Mn/m3, 
and presented increased GSH in the cortex while decreases wer seen in the caudate 
nucleus at 1.5 mg Mn/m3 (Erikson et al., 2007).  Results were similarly heterogeneous in 
another study by Erikson et al. (2004) using airborne Mn on 16 month old male rats and 
juvenile male and female rats.  An increase in GS protein was observed in both young 
and old male rats within the hippocampus and thalamus, while the olfactory bulb was the 
lone region in female rats with increased GS protein.  Decreases in GS and MT mRNA 
appeared to be age and sex dependent affecting the cerebellum, olfactory bulb, and 
hippocampus of young males, though decreased GS and MT mRNA were obsved in the 
hypothalamus of young females and hippocampus of old male rats.  Decreas s in GSH 
were also seen in the striatum of the old male and young female rats, and in the olfactory 
bulb of young males.  Interestingly young females exhibited an increase in GSH within 
the olfactory bulb.  These results indicate that while there are alterations in the 
antioxidant defense system, inconsistencies suggest the role of oxidative stress in 
neurodegenerative pathologies may be lower that originally thought.  A similar stance 
 
19 
was taken by Weber et al. (2002) when rat pups exposed to MnCl2 showed significant 
increases in cortical GSH, but no changes were observed in GSSG, MT, or GS levels.  
Conversely, data produced by Ali et al. (1995) identified a dose-dependent i crease of 
ROS in the caudate nucleus of Mn exposed rats, a region that significant decreases in 
GSH were reported by Desole et al. (1995), along with decreased GSH in isolated 
synaptosomes.   
 In vitro studies also tend to support the theory of Mn-induced oxidative stress.  
Significant decreases in GSH levels of RBE4 rat brain endothelial c lls exposed to 200 
µM Mn was associated with increased cell death (Marreilha dos Santos et al., 2008).  
Pretreatment with 500-1000 µM NAC spared RBE4 cell death, suggesting apoptosis was 
oxidative stress-induced.  Furthermore, SK-N-SH neuroblastoma cells treated with L-
buthionine sulfoximine (L-BSO), used to decrease cellular GSH, exhibited increased 
apoptosis when exposed to Mn or dopamine (DA) (Stokes et al., 2000).  Stredrick t al. 
(2004) examined the effects of 60 µM Mn on dopamine producing CATH.a cells and 
non-producing SK-N-SH cells, associating increase toxicity with CATH.a cells even after 
decreasing dopamine production with 100 µM α-methyl-para-tyrosine (AMPT).  
Formation of ROS was thought to play a role in apoptosis as the addition of 5 mM GSH 
or 10 mM NAC significantly protected CATH.a cell death.  Most recently, microglia are 
thought to contribute to Mn-induced free radical generation in dopaminergic neurons 
(Zhang et al., 2009).  Neuron-glial co-culture (containing microglia) and neuron-enriched 
culture (no microglia) were treated with 10-300 µM MnCl2.  Neuronal death was 
significantly more apparent in the neuron-glial co-culture than the neuron-enriched.  
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Furthermore, when microglia were introduced to the neuron-enriched culture similar cell 
death was observed as the neuron-glial co-culture.  Exposure to MnCl2 caused a robust 
increase in ROS that preceded neuronal damage, and the addition of SOD, catalase, GSH, 
or NAC significantly improved viability of cells exposed to Mn.  This finding provides 
evidence that intra- and extra-cellular Mn can induce ROS capable of damaging neurons.  
These data also suggest that astrocytes may play an important role in preventing neuronal 
damage by sequestering and concentrating extracellular Mn. 
F2-Isoprostanes 
 Overwhelming opinion suggests that oxidative stress plays a role in 
neurodegeneration.  However, until recently the only method to quantify the amount of 
oxidative stress in vivo was to observe the response of oxidatively sensitive proteins such 
as GSH, GPx, catalase, glutamine synthetase (an astrocyte specific enzyme highly 
sensitive to oxidative stress), and metallothionein.  No biological method had been 
identified to detect actual damage caused by oxidative injury until the development of F2-
Isoprostane (F2-IsoPs) quantification.  Isoprostanes (IsoPs) are a family of prostaglandin-
like molecules distinct in the fact that they are formed by free radical peroxidation of 
arachidonic acid independent of cyclooxygenase (Milne et al. 2008).  Formati n of IsoPs 
occurs while esterfied to phospholipids, and are released by phospholipase activity 
(Roberts and Milne 2008).  Because they are membrane bound when formed, it is thought 
that membrane fluidity and overall integrity may be altered as a result.  The F2 member of 
the IsoP family has become a reliable measure of oxidative injury, and F2-IsoP 
production has been implied in neurodegenerative disorders (Montine et al. 2004).  F2-
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Isops are stable molecules easily quantified; however, F2-IsoPs readily convert to E2 and 
D2 IsoPs in the presence of depleted cellular reducing agents such as GSH (Montine et al. 
2003).  E2/D2 IsoPs can later dehydrate to form A2 and J2 IsoPs, which due to their 
electrophilic nature, conjugate with GSH via GSH s-transferase for removal from the 
body (Milne et al. 2008; Chen et al. 1999).  Other than a marker for oxidative stess, F2-
IsoPs also have biological functions related to vasoconstriction.  F2 and E2 IsoPs have 
been shown to act on thromboxane receptors and to induce endothelin release, l ading to 
vasoconstriction in the brain (Morrow et al. 1992).  It is likely that e biological effect of 
IsoP formation encompasses more that what is known to this point.  However, given what 
has yet to be elucidated, IsoP quantification is still regarded as the gold standard of 
measuring in vivo oxidative damage. 
Treatments for Manganese Neurotoxicity 
 To date very few treatment options have been proposed for Mn neurotoxicity.  
Other than immediate removal from the Mn toxic environment two clinical treatments 
have been documented to improve neurotoxic symptoms, CaNa2EDTA and para-
Aminosalicylic Acid (PAS). 
CaNa2EDTA is a synthetic compound used in detergents and food preservatives 
that is known to bind divalent and trivalent metal ions.  A study by Hernandez et al. 
(2006) used CaNa2EDTA to treat seven welder/foundry workers presenting Mn induced 
Parkinson’s symptoms.  Five of the seven workers showed improvement in muscle 
rigidity and postural tremor.  The use of PAS as treatment for Mn intoxication was 
investigated in a case study of a 50 year old woman who had been exposed to airborne 
 
22 
Mn for 21 years.  All Mn-induced symptoms were significantly alleviated upon receiving 
PAS therapy, and the patient presented close to normal clinical, neurologic, MRI and 
handwriting scores in a follow up examination 17 yrs post treatment (Jiang et al. 2006). 
 Though CaNa2EDTA and PAS treatment have shown positive results, preventing 
Mn accumulation through reduced exposure is the best option to decrease neurotoxic 
damage due to Mn.  The use of antioxidant therapy has been suggested to do help protect 
against cellular damage associated with Mn neurotoxicity.  Several compounds have been 
identified as potential neuroprotectants including; ascorbic acid, α-tocopherol, NAC, and 
a growing number of polyphenolic compounds (PC).  These compounds help maintain 
cellular redox status protecting against Mn-induced free radical amage. One PC, in 
particular, that has shown promise as a neuroprotectant is (-)-epigallocatechin-3-Gallate 
(EGCG). 
 EGCG is thought to have strong antioxidant properties, stemming from multiple 
OH- groups projecting off of an electron stabilizing phenolic ring (Esposito et al., 2002).  
The antioxidant capability of catechins has been evidenced by EGCG attenuating the rise 
of SOD and catalase in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced 
toxicity (Levites et al., 2001).  Not only did EGCG attenuate the rise of SOD and catalase 
seen in MPTP toxicity, but it also decreased dopaminergic neuron loss in the mouse 
substantia nigra suggesting that electron donating from EGCG helped mitigate damage 
normally managed by cellular enzymes (Levites et al., 2001).  Additionally, EGCG has 
been shown to bind Fe2+, significantly decreasing DNA damage caused by the Fenton 
reaction (Perron and Brumaghim, 2009). Microarray analysis of specific apoptotic genes 
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was conducted in SH-SY5Y neuronal cell exposed to 1µM EGCG.  EGCG decreased 
expression of the pro-apoptotic genes bax, bad, caspase-1, caspase-6, p21, and gadd45 
(Weinreb et al., 2003).  Similarly, a study using mice fed 2 mg/kg EGCG showed 
significant decreases in Bax gene expression within the substantia nigra and hippocampus 
(Mandel et al., 2004).  Together these data support the hypothesis of antioxid t therapy 
as protection against Mn neurotoxicity.  However, questions remain regarding the 
bioavailability of EGCG in concentrations relevant to neuroprotection.  
Conclusion 
 While there is a solid foundation of literature examining Mn neurotoxicity, little 
experimental data has been published on the use of in vivo antioxidant therapy to 
attenuate Mn-induced damage.  The protective effect of antioxidant tre tment in vitro has 
been well characterized in both neurons and glial cells exposed to Mn.  However, it is 
still questionable whether the positive results seen in vitro can translate into a 
neuroprotective effect in vivo.  Additionally, if antioxidant therapy is successful in 
attenuating Mn-induced damage, will this be reflected in the behavior of these rats (e.g., 
normalize locomotor and anxiety-like neurological behaviors associated with 
neurotoxicity).  Mn has also been implied in the etiology of Parkinson’s disease, and 
attaining this information may play a critical role in testing the efficacy of antioxidant 
therapy as a potential treatment for neurodegenerative diseases.  To date it is unclear how 
much of a role Mn-induced oxidative stress plays in the neurochemical alterations present 
in Mn target regions.  Furthermore, does this dysfunction manifest as stereotypic 
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behavior changes analogous to those observed in early stage manganism, or motor 
function abnormalities indicative of Parkinson’s disease.  
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CHAPTER III 
THE EFFECT OF MANGNESE EXPOSURE, WITH AND WITHOUT 
N-ACEYTL-CYSTEINE AND (-)-EPIGALLOCATECHIN-3-
GALLATE THERAPIES, ON ANTIOXIDANT SYSTEMS IN THE 
RAT BRAIN 
 
 
Abstract 
 Manganese (Mn) is an essential element implicated in the etiologies of metal 
induced neurological disorders. Over-exposure to Mn results in its accumulation in iron-
rich brain regions leading to symptoms analogous to Parkinson’s disease.  Mechanisms 
governing this response are largely undefined though it is hypothesized that Mn-induced 
oxidative stress may play a role.  Previous studies have examined indirect oxidative 
markers such as glutamine synthetase, metallothionein, and glutathione (GSH) with 
mixed results.  In this study we examined weanling rats exposd to Mn (1 g/L d.i. water) 
for total GSH, glutathione peroxidase and catalase mRNA , and F2-isoprostane (F2-IsoP) 
production in the caudate putamen (CP) and hippocampus (HC), two regions previously 
identified to be affected by oxidative stress.  Randomly selected rats also received i.p. N-
acetyl-cysteine (NAC; 200 mg/kg) or (-)-epigallocatechin-3-gallate (EGCG; 5mg/kg) 
injections to observe any protective effect against Mn-induced oxi ative stress.  Mn 
exposure resulted in significant Mn accumulation versus control in each region (p < 
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0.05); however, this did not correspond to alterations in total GSH or producti n of F2-
IsoPs.  EGCG was also associated with significant Mn accumulation in the CP (p < 0.05).  
Significant up-regulation of GPx gene expression (p < 0.05) observed in the HC 
correlated with increased Mn levels, and was augmented by EGCG.  These data suggest a 
biological response in antioxidant gene expression to Mn exposure, even in the absence 
of identifiable oxidative stress.  Additionally, antioxidant therapy may enhance this 
response. 
Introduction 
 Manganese (Mn) is an essential dietary element involved in important biological 
processes related to energy metabolism, bone formation, blood clotting, cellular free 
radical defense, and neurotransmitter synthesis in the brain (Aschner et al., 2005).  
However, when exposed to excess amounts of environmental manganese neurological 
symptoms present in a condition coined “manganism.” The symptomology of manganism 
is similar to that of Parkinson’s disease in that each disrupts dopaminergic neurons in the 
basal ganglia leading to alterations in fine motor control, increased resting tremor, gait 
disturbances, and bradykinesia (Cersosimo and Koller, 2006).  Clinically, manganism is 
distinct in the lack of response to L-dopa treatment and early onset f anxiety and 
schizophrenic-like behavior (Cersosimo and Koller, 2006).  Cases of Mn toxicity have 
been reported in miners, welders, battery manufacturers, individuals exposed to 
contaminated drinking water, and in conditions altering hepatic function (Barceloux, 
1999).  Other populations at risk include neonates, patients receiving total parenteral 
nutrition, and those that are iron deficient (Aschner et al., 2005).  Recently, approval of 
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the anti-knock gas additive methylcylopentadienyl manganese tricarbonyl (MMT) has 
raised concern of the possible effect chronic low dose Mn exposure will have on toxic 
accumulation.  
 Mn toxicity is characterized by the accumulation of Mn in iron (Fe) rich regions 
of the brain, including the striatum, globus pallidus (GP), and substantia nigr  (SN) 
(Erikson et al., 2005a).  Altered dopamine transporter density in the striatum has been 
shown to facilitate Mn accumulation (Erikson et al., 2005b).  Additionally, damage to the 
GP and SN lead to perturbed dopaminergic communication between the SN and the 
striatum (Cersosimo and Koller, 2006).  Recent studies have shown that disturbances in 
γ-aminobutyric acid (GABA) and norepinephrine may precede dopaminergic changes 
and contribute to this dysfunction (Anderson et al., 2008, 2009).     
 Oxidative stress associated with Mn accumulation potentially contributes to 
neurochemical alterations observed in manganism.  Ali et al. (1995) reported a dose-
dependent increase in reactive oxygen species (ROS) in the caudate p tamen (CP) and 
hippocampus (HC) of Mn-exposed rats.  Increased ROS generation hs been linked to 
disturbances in mitochondrial membrane potential (Zhang et al., 2004) and inhibition of 
the electron transport chain (Bautista et al., 2000).  This may further propagate ROS 
through generation of superoxide radicals (Cassarino and Bennett, 1999).  Damage to 
mitochondria alters cellular Ca2+ homeostasis leading to apoptosis (Orrenius et al., 2007).  
Zhaoobao et al. (2008) demonstrated that ROS due to Mn compromised mitochondrial 
membrane potential leading to caspase-3 activation and subsequent apoptosis in primary 
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rat astrocytes.  This evidence provides reason to suspect that oxidative damage may lead 
to dopaminergic neuron loss reported in this pathway (Jenner and Olanow, 1996). 
 Glutathione (GSH) is an endogenous tripeptide that, under normal conditions, 
functions to conjugate and reduce cellular radicals (Dringen et al., 2000).  Aberrations in 
GSH due to Mn appear to be age and brain region specific.  Desole et al. (1995) reported 
decreased GSH in the CP of Mn-exposed aged rats, while increases in cortical GSH 
where found in Mn-exposed rat pups (Weber et al., 2002).  Inhalation studies in monkeys 
revealed increased GSH in the frontal cortex and decreased GSH in the caudate nucleus 
with 1.5 mg Mn/m3 MnSO4 exposure (Erikson et al., 2007).  The reason behind region 
specific GSH alterations has yet to be determined, and the biological response of GSH to 
Mn needs to be further characterized to understand these inconsistencies.  If indeed Mn-
induced oxidative stress plays a role in this relationship, it would be prudent to examine 
additional endogenous antioxidants that may affect GSH levels and function such as 
glutathione peroxidase (GPx) and catalase.   
 GPx is an enzyme that aids GSH in the reduction of cellular peroxides by 
transferring an electron from GSH, leaving GSH in its oxidized form (GSSG).  Catalase, 
a ubiquitous antioxidant enzyme, is responsible for converting H2O2 to H2O and O2.  
Altered function of GPx may decrease the ability of GSH to reduc  free radicals, and 
decreases in catalase could increase the antioxidant burden of GSH.  In theory, the use of 
neuroprotective antioxidant therapy could spare these systems in a pro-oxidant 
environment, and help illustrate if changes in GSH levels are due to Mn-induced 
oxidative stress.  
 
29 
 N-acetyl-cysteine (NAC) and (-)-epigallocatechin-3-gallate (EGCG) are two 
antioxidants known to cross the blood brain barrier.  NAC is a cysteine do or for GSH 
synthesis, and may directly scavenge free radicals with its iol functional group (Zhang 
et al., 2008).  Recently, EGCG has gained interest as a neuroprotective polyphenolic 
compound in the prevention of β-amyloid plaque formation in Alzheimer’s disease 
(Rezai-Zadeh et al., 2008).  EGCG may also act as an antioxidant using the electron 
donating potential of eight hydroxyl groups to reduce free radicals (Sjilata, et al., 2008).  
There is a growing body of research inspecting the effect of in vitro antioxidant 
treatments in the presence of Mn; however, little has been reported n the efficacy of in 
vivo antioxidant therapy in conjunction with Mn exposure. 
 The purposes of this study were to: 1) Examine the effect of Mn on GSH in two 
brain regions known to accumulate Mn (CP and HC); 2) Inspect the response of the 
antioxidant enzymes GPx and catalase to investigate their role in GSH functionality in an 
oxidative stress response; 3) Indirectly measure oxidative damage, in th  form of the lipid 
peroxidation byproduct F2-Isoprostanes (F2-IsoPs), to determine if Mn-induced oxidative 
stress plays a role in this process; 4) Establish whether in vivo antioxidant therapy can 
modulate these antioxidant systems in the presence of Mn-induced oxidative stress. 
Materials and Methods 
Animals 
 A total of 36 male 21-day-old Sprague-Dawley rats (Harlan Sprague-Dawley, 
Indianapolis, IN) were randomly divided into two exposure groups: control (CN; AIN-
93G diet, deionized water containing no Mn, n=18), or manganese exposed (Mn; AIN-
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93G diet, deionized water containing 1g Mn/L in the form of MnCl2, n=18).  Rats had 
free access to AIN-93G diet (Dyets Inc, Bethlehem, PA), and water 24 h/day.  Exposure 
groups where then assigned to receive one of three treatments via i.p. injection 3x per 
week: vehicle (Saline, n=6), N-acetyl-cysteine (NAC; 200mg/kg), or (-)-epigallocatechin-
3-gallate (EGCG; 5mg/kg) (Sigma-Aldrich Inc., St. Louis, MO) to yield a total of six 
treatment groups (CN, Mn, NAC, NAC-Mn, EGCG, EGCG-Mn).  Room temperature 
was maintained at 25 ± 1 °C, with dark cycle occurring between 1800 and 600 h.  After 
six weeks of treatment, rats were sacrificed, brains removed with the caudate putamen 
(CP) and hippocampus (HC) sectioned out using mapped stereotaxic coordinates 
(Paxinos and Watson, 1998).  Trunk blood and liver samples were also collected. Animal 
procedures were approved by The University of North Carolina at Greensboro Animal 
Care and Use Committee. 
Metal Analysis 
 Mn and Fe levels were quantified in dissected brain regions using graphite 
furnace atomic absorption spectrophotometry (Varian AA240, Varian Inc., USA).  Tissue 
was diluted 1:10 (w/v) in ultra pure nitric acid and placed in a 60°C sand b th overnight 
for digestion.  100 µl of diluted sample brought up to 1 ml with 2% nitric acid was used 
for analysis.  A bovine liver internal standard (10 µg Mn/g; 184 µg Fe/g) (NBS Standard 
Reference Material, USDC, Washington DC, USA) was used for quality control.  All 
metal results are expressed as µg/mg protein.  Protein levels were quantified using Pierce 
BCA Protein Assay (Thermo Fisher Scientific Inc., Rockford, IL).  
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Glutathione Analysis 
 
 Brain tissue was diluted 1:10 w/v in phosphate buffered saline (pH 7.4),
homogenized via sonication, and centrifuged at 10,000 x g for 15 min.  Supernatant 
collected was then deprotenated by adding an equal amount of metaphosphoric acid (5 g 
dissolved in 50 ml water) (Sigma-Aldrich Inc., St. Louis, MO), vortexed for 30 sec, and 
centrifuged at 3,000 x g for 2 min.  50 µl of 4 M triethalolamine (TEAM) (Sigma-Aldrich 
Inc., St. Louis, MO) was then added per ml of supernatant to increase sample pH.  Total 
glutathione levels were measured immediately after the addition of TEAM reagent using 
Glutathione Assay Kit (Cayman Chemical, Ann Arbor, MI).  Results are expressed as 
total glutathione equivalents per mg protein. 
GPx and Catalase mRNA 
 
 At sacrifice tissue samples of each sectioned brain region were submerged in 1ml 
RNAlater® solution (Ambion Inc., Austin, TX), and stored at -80°C.  RNA was isolated 
using the ToTALLY RNA™ kit (Ambion Inc., Austin, TX) as per manufacturer’s 
instructions.  RNA yield and purity was assessed using the A260:A280 ratio p oduced by 
NanoDrop spectrophotometry (Thermo Scientific, Delaware, MD).  To create cDNA a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City CA) 
was used following manufacturer’s instructions.  TaqMan® Gene Expression Assays were 
purchased to probe for GPx and catalase gene expression, in conjuncti with Universal 
PCR Master Mix (Applied Biosystems, Foster City CA).  GPx and CAT expression was 
normalized to β-actin expression for the same sample. 
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F2-Isoprostane Quantification 
 Isoprostane analysis was conducted in the Dr. Michael Aschner lab at Vanderbilt 
University using a gas chromatography/mass spec. method designed at Vanderbilt to 
specifically detect F2-Isoprostanes as outlined by Milatovic et al., 2007 and Morrow and 
Roberts, 1999. 
Statistical Analysis 
 
 Data were analyzed with SPSS version 14 for windows (Chicago, IL).  Outliers 
were removed using boxplot analysis, and resulting data were analyzed using two-way 
ANOVA with Mn levels and antioxidant treatment as between subjects’ effects.  
Dunnett’s procedure was applied when statistical between means was ignificant, p<0.05, 
to assess mean difference between treatment groups and control.  Pearson’s correlational 
analyses were used to examine the relationships between metal concentrations and GPx 
and catalase mRNA levels.  
Results 
 
Metal results 
 
 Mn concentrations in both the HC and CP were significantly higher (p < 0.05) in 
each Mn-exposed group compared to control (Fig. 3-1a, b).  Additionally i  the CP, 
EGCG treatment was independently associated with significant increases in both Mn (p = 
0.01) (Fig. 3-1a) and Fe (p = 0.006) (Data not shown).  In the HC, a similar trend was 
observed between EGCG and Mn though not significant (p = 0.108) (Fig. 3-1b).   
 Mn and Fe share a common transporter (DMT-1) at the blood brain barrier 
(Erikson et al., 2003). Due to this intricate relationship an Fe to Mn ratio (Fe:Mn) was 
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used to observe changes Mn-exposure had on Fe levels (Fig. 3-1c, d).  All Mn-exposed 
groups in the CP accumulated significantly less Fe than Mn-unexpos d groups (p < 
0.005).  The NAC treatment group exhibited the only significant (p < 0.005) Fe:Mn ratio 
in the HC with increased levels compared to control.  This indicates n increase in Fe 
accumulation, in the HC, with NAC treatment under normal levels of Mn.  
 
 
Figure 3-1.  Brain Metal Concentrations – CP and HC metal values expressed as 
percent control ± SEM, with the straight line representing mean control values.  Mn 
exposure significantly increased Mn accumulation in the caudate putamen (A) and the 
HC (B) versus control.  C) Decreased Fe:Mn ratios in the caudate putamen indicate Mn-
exposure significantly decreases Fe concentrations in these groups versu control.  D) A 
significant increase in the Fe:Mn of the NAC treatment group was observed compared to 
control. *p < 0.05 according to Dunnett’s post-hoc analysis. 
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Glutathione Results 
 The effect of Mn on GSH levels varied by brain region resulting in a 20% 
increase in the CP as opposed to a 20% decreased in the HC; however, neither was 
significant compared to control (Fig. 3-2a, b).  Treatment with NAC was independently 
associated with significantly decreased GSH levels compared to no antioxidant treatment 
(p = 0.010) and EGCG treatment (p = 0.018) in the CP (Fig. 3-2c).  A similar result was 
found in the HC, though NAC significantly decreased GSH only compared to the 
antioxidant free treatments (p = 0.031) (Fig. 3-2b). 
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Figure 3-2.  Glutathione Levels – Total glutathione levels in the caudate putamen and 
the hippocampus expressed as percent control ± SEM, with the straight line representing 
mean control values.  A)  No significant changes in glutathione levels were found in the 
caudate putamen.  B) A significant decrease in glutathione was observed in the 
hippocampus with the NAC treatment group.  C) NAC treatment independently 
decreased total glutathione levels compared to EGCG and no antioxidant treatment.  
*p<0.05 according to Dunnett’s post-hoc analysis. 
 
 
GPx and Catalase mRNA Results 
 Gene expression of GPx and catalase were quantified in the CP and HC to assess 
the response of antioxidant enzymes in the presence of Mn.  No significant changes were 
observed in catalase gene expression, in either the CP or HC, with most groups exhibiting 
slightly decreased values compared to control (Fig 3-3a, b).  Mn exposure in conjunction 
with NAC treatment significantly increased GPx expression in the CP (p = 0.001).  A 
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similar increase was observed in the HC, though not significant.  In the HC, EGCG 
treatment and Mn-exposure caused a near significant (p = 0.059) increase in GPx gene 
expression suggesting a biological response of GPx to Mn-exposure in th presence of 
antioxidants.  A significant positive correlation (p = 0.005) was also found in the HC 
between Mn and GPx with increased Mn levels associated with increased GPx gene 
expression.  
 
Figure 3-3.  GPx and Catalase Gene Expression – Effect of Mn and antioxidant 
therapies on catalase and glutathione peroxidase (GPx) gene expression.  A) In the 
caudate putamen up-regulated GPx gene expression was observed in the NAC-Mn 
treatment group.  B) A near significant (p = 0.059) increase in GPx gene expression was 
observed in the hippocampus of Mn-exposed rats receiving EGCG therapy.  C) A 
positive correlation between Mn accumulation and increased GPx gene expr ssion was 
observed in the hippocampus of juvenile rats.  *p<0.05;  † - p<0.1 according to Dunnett’s 
post-hoc analysis. 
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F2-Isoprostane Results 
  No significant changes in F2-IsoPs were apparent in the HC with or without Mn 
exposure and/or antioxidant treatment (data not shown).  In the CP significant decreases 
in F2-IsoPs were observed in each group compared to control (data not shown).   
Discussion 
 
 These data suggest that Mn accumulation elicits a biological response in 
antioxidant enzymes, specifically GPx, which is amplified by antioxidant therapy. Mn 
accumulated significantly in the CP and HC of Mn-exposed rats (Fig. 3-1a, b).  This was 
accompanied by a significant positive correlation between Mn and GPx gene expression 
(Fig. 3-3c).  NAC and EGCG therapies amplified this relationship (Fig. 3-3) which 
appeared to be independent of changes in total GSH levels (Fig. 3-2).  Slight alterations 
were observed in GSH levels, though none were significant in the presnce of Mn (Fig 3-
2a, b).  However, NAC therapy significantly decreased GSH levels compared to EGCG 
and antioxidant free treatments (Fig. 3-2c).  Interestingly, no evidence of increased 
oxidative damage was observed via F2-IsoP analysis (data not shown).  However, this 
finding may not be representative of the biological environment due to limited 
availability of tissue for F2-IsoP analysis and possible auto-oxidation of the control 
samples which measured abnormally high (discussed below).  Taking this into account, 
increased GPx gene expression suggests that Mn toxicity elicits an oxidative stress 
response, even in the absence of apparent oxidative stress.  Furthermore, antioxidant 
therapy seemed to reinforce the antioxidant gene expression response.   
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 Mn exposure via drinking water significantly increased Mn levels in both the CP 
and the HC and decreased the Fe:Mn ratio (a marker of divalent metal homeostasis) (Fig. 
3-1c, d), consistent with findings previously reported in our lab (Anderson et al., 2008).    
However, the introduction of NAC and EGCG therapies produced a few novelfindings 
with respect to brain metal homeostasis.  EGCG therapy significa tly increased Mn 
accumulation in the CP in both EGCG and EGCG-Mn treatment groups (Fig 3-1a).  
EGCG was also independently associated with increased Fe levels in the CP (data not 
shown).  A 2007 study by Perron et al. identified the ability of EGCG to mitigate DNA 
damage by chelating Fe, thereby decreasing Fe-induced ROS.  Perron d monstrated that 
EGCG forms a complex between its three polyphenolic gallate substituents and multiple 
Fe ions.  Because Fe, Mn, and other divalent metals have comparable reactive properties, 
the possibility of Mn forming a similar complex with EGCG is likely.  Additionally, the 
chelating properties of EGCG may decrease the oxidative threat of divalent metals in the 
brain.  This raises an interesting question as to whether or not EGCG may chaperone Fe 
and/or Mn to, from, or within the brain.  Evidence of EGCG in the brain after oral 
administration confirms permeability at the blood brain barrier (BBB), and it is suggested 
that methylation of EGCG in the liver may aid in this process (Youdim et al., 2004; 
Mohsen et al., 2002).  Methylation may create a more hydrophobic compound allowing 
for passive transcellular diffusion at the BBB and choroid plexus (Youdim et al., 2004).  
To date no specific transporters have been identified, though there seems to be interaction 
between EGCG and P-glycoprotein efflux pumps.  Jodoin et al. (2002) demonstrated that 
EGCG and other green tea polyphenols reversibly inhibit P-glycoprotein pumps allowing 
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for delivery of cancer drugs to the multi-drug resistant cell line CHRC5.  This introduces 
the possibility that EGCG may alter other transport proteins allowing for its passage after 
binding Fe, or potentially Mn. 
  Interestingly, the increased metal concentration in the CP did not lead to 
significant alterations in GSH, GPx, or catalase.  Discrete changes in GSH were observed 
in the CP (Fig. 3-2a), with the Mn group exhibiting the largest change (a 20% increase in 
GSH levels compared to control).  This finding, albeit not significant, is contradictory to 
reports of decreased GSH in the CP of aged rats (Desole et al., 1995), but complementary 
to previous findings by Erikson et al. (2004) and Dobson et al. (2003) in which no 
significant changes in striatal GSH levels in rats exposed to airborne Mn were shown.  
Alternatively, neonatal rats exposed orally to MnCl2 exhibited increased cerebrocortical 
GSH levels while no changes in metallothionein (MT) or glutamine sy thetase (GS) were 
observed (Weber et al., 2002).  Brain regional GSH in the basal ganglia were not reported 
by Weber et al., and the authors felt it was unlikely oxidative stres  played a role in GSH 
changes.  MT and GS proteins, like GSH, are sensitive indirect markers of oxidative 
stress.  MT is a metal binding protein with cysteine residues capable of neutralizing free 
radicals (Erikson et al., 2008), and GS is an astrocyte specific nzyme highly sensitive to 
oxidation (Stadtman and Berlett, 1997).  Mn inhalation studies in primates use all thre of 
these indexes in accessing oxidative stress.  Two studies by Erikson et al. (2007; 2008) 
exposed monkeys to airborne Mn-sulfate, each reporting decreased GSH in the caudate 
nucleus along with decreased GS in the globus pallidus after 45 and 65 day exposure, 
respectively.  Interestingly, GSH decreases in the caudate nucl us were accompanied by 
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increased GSH in the putamen (the caudate and putamen collectively form the striatum) 
after 65 day exposure suggesting that Mn exposure affects individual brain regions 
differently.  These alterations persisted even after 90 day removal from airborne 
exposure.  Inhalation studies in rats using Mn-sulfate revealed similar decreases in GSH 
within the CP (Taylor et al., 2006).  Differences between exposure protocols, inhaled v. 
ingested, may influence the impact of Mn accumulation on GSH, and overall oxidative 
stress.  Studies, such as ours, using oral Mn exposure via drinking water show little 
evidence of Mn-induced oxidative stress compared to inhalation studies.  Furthermore, 
brain Mn levels in our study were 10-100 times lower than brain regional Mn reported by 
Dorman et al., 2006 in rhesus monkeys.  However, we did observe similar percent control 
increases in Mn-exposed groups.  Decreased Mn levels (µg Mn/g tissue) in oral exposure 
could stem from intestinal regulation of metal absorption by DMT-1.  Airborne Mn is not 
subject to this homeostatic regulation in either the lungs or by transport down the 
olfactory nerve, resulting in greater brain Mn accumulation and potentially increased 
oxidative damage. This suggests that oral Mn exposure, while still accumulating 
significantly compared to control, may not reach levels high enough to induce notable 
oxidative stress.     
 Antioxidant therapy had little impact on GSH levels.  In the HC, decreased GSH 
found in the NAC group was the only significant change we observed (Fig. 3-2b), and 
this effect was abolished by Mn.  One would expect an increase in GSH levels due to 
NAC, an active cysteine donor and GSH precursor, though this was not the case.  In fact 
NAC treatment significantly reduced GSH levels compared to EGCG and antioxidant 
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free groups (Fig. 3-2c).  The reduction in GSH that we observed could be due to NAC 
directly scavenging free radicals, in effect sparing GSH thereby decreasing cellular 
production.  This finding opposes the growing body of in vitro research illustrating 
increased GSH levels in response to NAC treatment under Mn exposure: NAC (500-1000 
µM) increased GSH and spared Mn-exposed RBE4 cell death (Marreilh  do Santos et al., 
2008); CATH.a cells treated with 10 mM NAC and 5 mM GSH protected against Mn-
induced cell death (Stredrick et al., 2004); NAC treatment improved viability of Mn-
exposed neuron-glial co-cultures (Zhang et al., 2009).  A critical differenc between these 
in vitro studies and our study is that we were not able to demonstrate a depletion of GSH 
definitively due to oxidative stress.  The biological response of NAC in vivo may differ 
from that of cell studies, and the protective effect of NAC could be a graded response to 
declining GSH levels.  It is also important to note that necropsy analysis of animals 
receiving i.p. NAC injections revealed significant inflammation of the liver and intestinal 
tract accompanied by a substantial decrease in gut motility.  To our knowledge this is the 
first time NAC has been administered via i.p. injection for a chronic treatment protocol 
(3x per week for 6 weeks).  Oral, topical, and intravenous administration re commonly 
used to deliver NAC in colon cancer, HIV, and cardio pulmonary studies (Atkuri et al., 
2007).   
 We observed that Mn had a significant effect on GPx gene expression (Fig. 3-3c), 
and that EGCG and NAC amplified this response (Fig. 3-3a, b).  These results did not 
appear to be driven by oxidative stress, as there was no significant increase in F2-IsoP 
levels observed (data not shown).  Isoprostane analysis has emerged as a reliable 
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indicator of lipid peroxidation (Montine et al. 2004).  However, proper tissue 
preservation is critical to accurately quantify F2-IsoPs.  F2-IsoPs readily convert to E2 and 
D2 IsoPs in the presence of depleted cellular reducing agents such a  GSH, and propagate 
in a pro-oxidant environment (Montine et al. 2003).  The control tissue we analyzed for 
F2-IsoPs measured abnormally high skewing comparisons between groups.  It is possible 
that the brain regions in these animals were not dissected or flash frozen quickly enough 
to prevent auto-oxidation of the tissue.  Because we were unable to quantify F2-IsoPs in 
our control samples we can not definitively say that no oxidative damage was present due 
to Mn exposure compared to control.  Additionally, increased GPx gene expr ssion did 
not correspond with alterations in GSH.  Together these findings suge t that Mn-
induced oxidative stress appears to play a minimal role in up-regulat d antioxidant 
enzymes, but the presence of Mn did lead to increased GPx, perhaps by n alternate 
mechanism.  Catalase levels, alternatively, remained stable across all treatment groups in 
the CP, decreasing slightly in the HC of all treatment groups compared to controls (Fig 
3b).  Neither antioxidant treatment nor Mn-exposure altered mRNA levels.  This finding 
supports our thought that the free radicals generated, if any, were not significant enough 
to tax cellular antioxidant defense. 
Data obtained in this experiment align with previous findings that Mn exposure leads 
to significant Mn accumulation in the CP and HC of rats.  Additionally, our results reveal 
a positive correlation between Mn accumulation and increased GPx gene expression.  
Antioxidant therapy with NAC and EGCG amplified this response implying a potential 
neuroprotective effect.  Oxidative stress was not evident in these brain regions, and only 
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modest alterations were observed in total GSH levels.  This could suggest that oral Mn 
exposure, though still neurotoxic, may not be as deleterious as inhalat on exposure.  
Increased Mn due to oral exposure may elicit subtle neurochemical alterations leading to 
altered behavior and cognitive function, whereas airborne exposure leads to more robust 
Mn accumulation, oxidative stress, and potentially a neurodegenerative state.  However, 
further work needs to examine the effect of oral Mn exposure in other regions of the basal 
ganglia, such as the globus pallidus and the substantia nigra.  These regions, along with 
the cortex, are integral to the neural circuitry associated with processing and executing 
movement patterns and behaviors commonly altered by Mn neurotoxicity.  
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CHAPTER IV 
THE EFFECT OF WATER-BORNE MN EXPOSURE AND 
SUBSEQUENT ANTIOXIDANT TREATMENT ON STEREOTYPIC 
BEHAVIORS IN RATS 
 
 
Abstract 
 Manganese (Mn) is an essential element critical to normal neurological function.  
It has been well documented that excessive exposure to Mn can result in neurotoxic brain 
accumulation leading to symptoms resembling neurodegenerative disorder , such as 
Parkinson’s disease.  Behavioral alterations are known to occur in these disorders, but 
few studies have examined behavior abnormalities associated with neurotoxic Mn 
exposure.  In this study we examined the effect of water-borne Mn exposure on 
stereotypic behaviors in rats.  Additionally, oxidative stress has been implied in the 
etiology of Mn neurotoxicity, because of this we applied N-acetyl-cysteine (NAC) and (-
)-epigallocatechin-3-gallate (EGCG) antioxidant therapies to observe if protection from 
oxidative stress would correct any behavior abnormalities.  Twenty-one day old Sprague-
Dawley rats were exposed to Mn via drinking water (1 g Mn/L) and either 200 mg/kg 
NAC or 5 mg/kg EGCG thee times a week for six weeks.  Rat behaviors were monitored 
for a 24 hour period during the sixth week with Clever Systems Home Cag  Scan video 
surveillance.  Locomotor behavior was assessed by calculating total dis ance traveled, 
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and time spent sleeping, sniffing, and grooming were monitored to reflect anxiety-like 
changes in behavior.  Mn significantly accumulated in the caudate pu amen and 
hippocampus of exposed rats, and was positively correlated with total dist nce traveled 
(p<0.05).  Mn also significantly decreased sniff behavior, but little eff ct was observed in 
sleeping and grooming behaviors.  Antioxidant therapy had no effect on anxiety 
behaviors in Mn-exposed groups, but was associated with increase locomot r activity.  
These data indicate that oral Mn exposure is associated with locomotor abnormalities, but 
minimally alter anxiety-like behavior.  Additionally, NAC and EGCG antioxidant therapy 
plays a minimal role in preserving behavior changes in the presence of Mn. 
Introduction 
 Dietary metals play an essential role in many biological processes ranging from 
energy metabolism and bone health to neurological function (Aschner et al., 2005).  
Manganese (Mn), specifically, functions as a cofactor for glycolytic enzymes, aids in 
blood clotting, and is required for ammonia clearance from the brain (Aschner et al., 
2005; Takeda, 2003).  Perturbed metal homeostasis can have detrimental eff cts on these 
systems, and has been reported in occupational settings related to mining, welding, and 
battery manufacturing (Dobson et al., 2004).  In these settings over exposure to Mn 
usually occurs due to increased airborne Mn particulate, giving rise to a neurotoxic 
condition known as “manganism.”   
 A hallmark of manganism is increased accumulation of Mn in iron (Fe) rich areas 
of the brain.  Studies in these populations using magnetic resonance imaging (MRI) 
repeatedly show increased Mn accumulation in the globus pallidus compared to normal 
 
46 
individuals (Kim et al., 2007; Park et al., 2007; Kim, 2004).  Manganism is also 
accompanied by neurological symptoms related to locomotion and alter behavior 
(Dobson et al., 2004).  General symptoms include fatigue, loss of appetite, insomnia, and 
headache (Pal et al., 1999), with progression to violent behavior, emotional d stress, and 
hallucinations (Aschner et al., 2005).  Early onset of the disorder is associated with 
anxiety and schizophrenic like behavior (Pal et al., 1999).  It is believed that alterations in 
neurotransmitter systems, in particular, dopamine (DA) drive these symptoms 
(McDougall et al., 2008). 
 Mn neurotoxicity is also similar to Parkinson’s disease with respect to damage 
within the globus pallidus and substantia nigra leading to altered dopamine levels in the 
striatum (Cersosimo and Koller, 2006).  The loss of striatal dopamine co tributes to the 
symptomatic dysfunction shared by the two disorders. The majority of Mn research has 
focused on perturbations in the nigrostriatal dopaminergic pathway, however, it has 
recently come to light that preceding alterations in γ-aminobutyric acid (GABA) and 
norepinephrine (NE) may contribute to dysfunction (Anderson et al., 2008, 2009). 
 Relationships between behavior, locomotion, and Mn exposure have been furth r
studied in rodent models with varying results.  A study conducted by Calabresi et al. 
(2001) reported that rats exposed to Mn exhibited significantly increased activity in open 
field tests with little habituation.  This contradicts a previous finding by Talavera et al. 
(1999) demonstrating decreased activity in Mn-exposed mice.  Additionally, no 
significant activity changes were observed in neonatal rats receiving oral Mn, though 
increased startle response was noted (Dorman et al., 2000).  Evidence from other rodent 
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studies supports the involvement of DA in locomotor behavior.  When the DA transporter 
(DAT) gene expression was disrupted in mice resulted in hyper-locom tion (Giros et al., 
1996).  This was supported in DAT knockout mice that had high extracellular dop mine 
and increased locomotion (Spieleway et al., 2000).  In rat models of hyperactivity, 
intracisternal injections of 6-hydroxydopamine increased gene expression of striatal N-
methyl-D-aspartic acid (NMDA) receptors and decreased GABA transporter expression 
suggesting a role of GABA and glutamate in increased locomotor ac ivity (Masuo et al., 
2004).  
 Though Mn is the principle metal of interest in locomotor abnormalities 
associated with Manganism, the relationship between Mn and Fe homeostasis should be 
considered as well.  An intricate relationship exists between Mn and Fe as the two share 
common absorption and transport mechanisms within the body, primarily via the divalent 
metal transporter DMT-1 (Aschner, 2006; Erikson and Aschner, 2006).  In fact, as Fe 
levels decline, increased Mn is absorbed in the intestines followed by augmented 
transport of Mn into the brain (Erikson et al., 2002a).  Decreased Fe levels have also been 
associated with decreased activity and increased anxiety-like behaviors in rats (Beard et 
al., 2002).  This suggests that neither should be exclusively examined in behavioral 
studies.  
 Previous data collected in our lab uncovered some interesting associations 
between dietary Fe deficiency, Mn exposure, and behavior alterations in the home cage 
environments of rats.  The purpose of this study was to further characterize the 
relationship between Mn and Fe homeostasis with behavior by using 24-hour video 
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surveillance, and to assess any effect of antioxidant treatment on the behavior of Mn-
exposed rats.  
Materials and Methods 
 
Animals 
 
 A total of 36 male 21-day-old Sprague-Dawley rats (Harlan Sprague-Dawley, 
Indianapolis, IN) were randomly divided into two exposure groups: control (CN; AIN-
93G diet, deionized water containing no Mn), or manganese exposed (Mn; AIN-93G diet, 
deionized water containing 1g Mn/L in the form of MnCl2).  Rats had free access to AIN-
93G diet (Dyets Inc, Bethlehem, PA) and water 24 h/day.  Exposure groups where then 
randomly assigned to receive one of three treatments via i.p. injection: vehicle (Saline, 
n=6), N-acetyl-cysteine (NAC; 200mg/kg), or (-)-Epigallocatechin-3-gallate (EGCG; 
5mg/kg) (Sigma-Aldrich Inc., St. Louis, MO) to yield six groups CN, Mn, NAC, NAC-
Mn, EGCG, and EGCG-Mn.  Room temperature was maintained at 25 ± 1°C, with dark 
cycle occurring between 1800 and 600 h.  Animal procedures were approved by The 
University of North Carolina at Greensboro Animal Care and Use Committee. 
Metal Analysis 
 
 After week six rats were sacrificed, brains removed, and brain regions of interest 
sectioned out (caudate putamen (CP) and hippocampus (HC)) using mapped stereotaxic 
coordinates (Paxinos and Watson, 1998).  Mn and Fe levels were quantified i  dissected 
brain regions using graphite furnace atomic absorption spectrophotometry (Va ian 
AA240, Varian Inc., USA).  Tissue was diluted 1:10 weight to volume (w/v) in ultra pure 
nitric acid and placed in a 60°C sand bath overnight for digestion.  100 µl diluted sample 
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brought up to 1 ml with 2% nitric acid was used for analysis.  A bovine liver internal 
standard (10µg Mn/g; 184µg Fe/g) (NBS Standard Reference Material, USDC, 
Washington DC, USA) was used for quality control.  All metal results are expressed as 
µg/mg protein.  Protein levels were quantified using Pierce BCA Protein Assay (Thermo 
Fisher Scientific Inc., Rockford, IL).  
Behavior Analysis 
 
 Behavior analysis was collected during weeks four, five, and six of dietary and 
antioxidant protocol using Clever Systems Home Cage Scan (HCS) video equipment and 
software (Reston, VA).  This software was designed to automatically score behavior by 
analyzing sequential frame by frame animal postures in space.  Animal postures are 
determined 30 frames per second by referencing anatomical features in relationship to 
one another against other customized cage landmarks.  Accuracy of HCS scoring has 
been verified by manual assessment to be ≥ 90% (Steele et al., 2007).  Rats are placed in 
shoebox cages including food, water, and minimal bedding and individually recorded for 
a continuous 24hr period.  During the dark cycle cages were backlit with red light to 
allow for video capture.  Behaviors monitored include: drinking, eating, sleeping, 
grooming, and sniffing.  Total distance traveled was also calculated to assess activity.  
Only week six data is reported as no significant differences emerged between groups in 
weeks four and five. 
Statistical Analysis 
 
 Data were analyzed using SPSS version 14 for windows.  Outliers were removed 
using boxplot analysis, and resulting data were analyzed using analysis of variance.  
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When statistical analyses yield significance, p<0.05, Dunnett’s procedure was used to 
analysis mean difference between treatment groups and control.  Pearson’s correlational 
analysis was used to report associations between metal levels and reported behaviors.  
Results were considered significant with p < 0.05.  
Results 
Metal Results 
 Mn concentrations in both the HC and CP were significantly higher (p < 0.05) in 
each Mn-exposed group compared to control (Fig. 4-1a, b).  Additionally in the CP, 
EGCG treatment was independently associated with significant increases in both Mn (p = 
0.01) and Fe (p = 0.006) (Data not shown).  In the HC, a similar trend was observed 
between EGCG and Mn though not significant (p = 0.108) (Fig. 4-1b).   
 Mn and Fe share a common transporter (DMT-1) at the blood brain barrier 
(Erikson et al., 2003). Due to this intricate relationship an Fe to Mn ratio (Fe:Mn) was 
used to observe changes Mn-exposure had on Fe levels (Fig. 4-1c, d).  All Mn-exposed 
groups in the CP accumulated significantly less Fe than Mn-free groups (p < 0.005).  The 
NAC treatment group exhibited the only significant (p < 0.005) Fe:Mn ratio in the HC, 
with increased levels compared to control.  This indicates an increase in Fe accumulation, 
in the HC, with NAC treatment under normal levels of Mn.  
 
 
51 
Figure 4-1.  Brain Metal Concentrations – CP and HC metal values expressed as 
percent control ± SEM, with the straight line representing mean control values.  Mn 
exposure significantly increased Mn accumulation in the caudate putamen (A) and the 
HC (B) versus control.  C) Decreased Fe:Mn ratios in the caudate putamen indicate Mn-
exposure significantly decreases Fe concentrations in these groups versu control.  D) A 
significant increase in the Fe:Mn of the NAC treatment group was observed compared to 
control. *p < 0.05 according to Dunnett’s post-hoc analysis. 
 
 
Distance Traveled 
 Distance traveled was significantly increased in the Mn (p = 0.02) and EGCG-Mn 
(p = 0.029) groups compared to control (Fig. 4-2a), with a trend toward significance 
observed in the NAC-Mn group (p = 0.071).  Increased CP and HC Mn levels were 
significantly correlated with this result (p = 0.017 and 0.001, respectively) (Fig. 4-2c, d), 
as well as decreased Fe:Mn ratios in the CP (p = 0.008) and HC (p = 0.001) (Fig. 4-2e, f).
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Figure 4-2.  Distance Traveled and Sleep Patterns A) Total distance traveled during 
week six, expressed as % Control.  Mn exposure significantly increased total distance 
traveled during week six.  B) Sleeping patterns expressed as a Light:Dark ratio (time 
spent sleeping during the light cycle divided by time sleeping during the dark cycle).  
Mn-exposed rats slept less during the dark cycle, which corresponds with increased total 
distance traveled.  A positive correlation was found between Mn levels in the CP (C) and 
the HC (D) and total distance traveled (p = 0.017 and 0.001, respectively).  A negative 
correlation was observed between Fe:Mn ratio in the CP (E) and the HC (F) and total 
distance traveled (p = 0.008 and 0.001, respectively).  *p < 0.05   †p < 0.1 according to 
Dunnett’s post-hoc analysis.  Pearson’s analysis used to establish correlational 
significance.  
 
Sleeping 
 No significant differences were observed between groups after analyzing sleep 
behaviors (Fig. 4-2b).  Mn exposure did not appear to alter circadian rhythm, evidenced 
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by slight increases in Light:Dark ratio (Fig. 4-2b).  This increase indicates the majority of 
sleep occurred in the light cycle, consistent with normal behavior.  
Grooming 
 Mn exposure caused an increase in grooming activity during the dark cycle (Fig. 
4-3a).  A trend toward significance was observed in the dark to light cycle groom ratio 
with CP Fe:Mn ratio (p = 0.106) (Fig. 4-3a inset).  However, the EGCG-Mn group did 
not display as marked an increase over EGCG as Mn v. CN or NAC-Mn v. NAC. 
Sniffing 
 A significant decrease in sniffing behavior between the Mn and CN group was 
observed (p = 0.05) (Fig. 4-3b).  A similar, near significant (p = 0.068), decrease was 
seen in the EGCG-Mn group versus CN (Fig. 4-3b).  Overall, decreased sniffing behavior 
correlated with increased HC Mn levels (p = 0.044) (Fig. 4-3b inset). 
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Figure 4-3.  Groom and Sniff Behaviors A) Time spent grooming expressed in a 
Dark:Light ratio (time spent grooming during the dark cycle divided by time in the light).  
Increased grooming behavior was observed in Mn and NAC-Mn groups, which correlated 
with decreased Fe:Mn ratios in the CP (figure inset) (p = 0.106).  B) Sniff behavior 
expressed in a Dark:Light ratio.  The Mn groups engaged in significantly less sniffing 
behavior in the dark, than light, compared to CN (p = 0.05).  Similarly, a trend toward 
significance was observed in decreased sniffing behavior of EGCG-Mn rats compared to 
CN (p = 0.065).  Overall, decreased Dark:Light sniff ratios were correlated with 
increased Mn levels in the HC (p = 0.044). *p < 0.05  †p < 0.1 according to Dunnett’s 
post-hoc analysis.  Pearson’s analysis used to establish correlational significance.  
 
Discussion 
 Results obtained from this study indicate that Mn exposure does correlate strongly 
with altered locomotor activity.  We did not measure neurotransmitter levels directly in 
this experiment, but neurochemical alterations in rodents are generally reflected by 
changes in locomotor activity (Flagel and Robinson, 2007).  Additionally, Mn exposure 
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alone was sufficient to produce Mn accumulation in the CP and HC, as well as perturb Fe 
levels to an iron deficient (ID) like state in the brain.  Both ID and Mn toxicity are known 
to affect neurochemistry (Beard et al., 2002; Anderson et al., 2008; 2009), and may drive 
changes observed in stereotypic behaviors.  Our results also indicate that NAC and 
EGCG antioxidant therapy plays a minimal role in preserving behavior changes in the 
presence of Mn. 
 Delivery of Mn via water consumption was successful in producing Mn 
accumulation in the CP and the HC of rats exposed.  This result corroborated previous 
findings in our lab (Anderson et al., 2008; 2009).  However, the preceding behavior trial 
utilized manipulations in Mn as well as dietary ID.  This treatment protocol only yielded 
significant ID in the CP and globus pallidus (GP), with significant Mn accumulation 
limited to the CP and HC of rats exposed to both Mn and dietary ID.  The inability to 
produce a robust brain metal response with the treatment protocol may have muted the 
behavioral response to altered metal homeostasis.  Taking this into account, our current 
study eliminated the ID aspect of the treatment protocol.  Mn exposure alone was 
sufficient to induce brain Mn accumulation and decrease brain Fe levels by presumably 
overwhelming the shared transport mechanism, DMT-1.  Indeed, by solel manipulating 
Mn we observed a significant increase in Mn accumulation along with significantly 
decreased Fe:Mn ratios.  Due to this protocol adjustment we were unable to examine the 
behavioral effects of frank ID, which is associated with neurochemical changes of its 
own, as well as propagating Mn accumulation.  However, this allows us to observe the 
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behavioral changes associated with Mn-driven alteration in metal homeostasis, perhaps 
more analogous to those experienced in manganism.   
 Locomotor abnormalities have been associated with manganism (Dobson et al., 
2004).  When assessing locomotor activities in rats, total distance trav led is widely 
accepted to reflect neurochemical alterations (Flagel and Bobinson, 2007).  We observed 
an increase in total distance traveled due to Mn exposure and a decreased Fe:Mn ratio.  
Both Mn and Fe are known to alter locomotor activity, and it is thought that changes in 
DA levels drive these alterations (Beard et al., 2002; Normandin et al., 2004; Le Moal, 
1995).  There are, however, different reports on locomotor behaviors associated w th ID 
versus Mn toxicity.  Beard et al. (2002) reported decreased overall locomotor activity in 
ID rats associated with decreased DA receptor and transporter densities.  While Mn 
studies have revealed both increased and decreased activity levels depending on route a d 
duration of Mn exposure.  Specifically, thirteen week exposure to 30, 300, or 3 00 µg/m3 
airborne Mn phosphate resulted in no changes in locomotor activity in rats (Normandin et 
al., 2002).  A later study by the same group revealed that utilizing the same dosing 
protocol with a Mn sulfate/Mn phosphate mix cause a significant decrease in spontaneous 
motor activity (Normandin et al., 2004), suggesting that the species of Mn delivery may 
play a role in its neurotoxic effects.  This differential effect corroborated an earlier 
toxicokinetic study examining the effect of Mn particle size and relative solubility on 
toxic outcomes (Barceloux, 1999 for review).  Using the identical Mn sulfate/Mn 
phosphate inhalation model, Tapin et al. (2006) reported a significant increase in total 
distance traveled, contradictory to previous findings.  Neuropathological analysis of the 
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GP and CP, conducted by Tapin, revealed a significant decrease of pallidial neurons in 
Mn exposed groups compared to control.  This could be a potential upstream trigger to 
increased DA release in the nigrostriatal pathway (which has been associated with 
increased locomotion; Le Moal, 1995), by decreasing GABAergic firing from the GP 
onto the subthalamic nuclei (STN), which in turn would cause dysinhibition of glutamate 
firing from the STN into the substantia nigra (SN) leading to increased DAergic 
neurotransmission into the CP.  This would be consistent with findings in GABAB
-/- 
receptor null mice that reported hyperlocomotion upon introduction to a novel 
environment (Vacher et al., 2006), and reported decreased GABAB mRNA levels in the 
SN due to Fe:Mn alterations (Anderson et al., 2008).  This hypothesis hinges on the loss 
of neurons due to Mn exposure, and suggests coordination of multiple neurotransmit er 
systems demonstrating the complexity of a neurobehavioral response.  
 Similar variations in locomotor behaviors are found in studies using oral Mn 
exposure.  We observed an increase in total distance traveled with 1g Mn/L via MnCl2 in 
the drinking water after 6 weeks of exposure.  Calabresi et al. (2001) reported a 
significant increase in activity during open field tests in rats ingesting 20 mg Mn/ml 
water for 10 weeks.  Dorman et al. (2000) observed no change in motor activity neonatal 
rats exposed to 0, 25, or 50 mg/kg/day via MnCl2 drinking water, with increase striatal 
DA levels.  And significant decreases in total distance traveled were reported after 19 
week oral exposure to 550 mg Mn/kg/day (Torrente et al., 2005).  It is clear that 
variations in dose and duration of oral Mn exposure have an effect on observed 
locomotion, with longer durations at higher doses resulting in decrease motor activity.  
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Even thought brain accumulation of Mn is similar in these cases, chroni  exposure may 
lead to increase neuronal damage eventually decreasing neurotransmitter output, 
specifically DA.  Acute Mn exposure is known to alter neurotransmitter transporter and 
receptor gene expression resulting in increased synaptic neurotransmitter concentrations 
(Anderson et al., 2008; 2009).  These alterations may induce locomotor abnormalities 
(increased activity) over short durations (6-10 weeks).  Decreased activity observed with 
chronic exposure (11+ weeks) may be indicative of further neuronal dysfunction in an 
advanced diseased state.  Similarly, age may play a role in th behavioral response to Mn 
accumulation.  Increases in striatal DA is normally associated with increased locomotion 
(Le Moal, 1995); however, this finding in neonatal rats versus weanling rats may be the 
result of more severe developmental problems resulting in a general malaise. 
 Other behaviors examined in the current study (sleeping, sniffing and grooming) 
seemed to be less sensitive to acute Mn exposure.  Mn-exposed rats spent comparatively 
more time sleeping during the light cycle than dark.  This is contradictory to data 
previously collected in our lab suggesting that decreased Fe:Mn ratios lead to a partial 
reversal in circadian rhythm.  ID has been shown to alter circadian rhythm (Youdim et 
al., 1980), as have disturbances in GABA biology (Crosio et al., 2000; Vacher et al., 
2006).  Decreases in Fe:Mn ratio in the current study may not elicit the same 
neurochemical response as frank ID which may account for differences in this observed 
behavior.   
 Sniffing and grooming behaviors were used as exploratory behaviors in the 
current study to assess anxiety-like behavior alterations.  While we did see a significant 
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decrease in sniffing behavior in the Mn treated group, grooming increased during the 
dark cycle of Mn and NAC-Mn groups, though not significant.  This differs rom a study 
by Vezer er al. (2005) where increased HC Mn concentrations were correlated with 
decreased grooming at exposure week 10.  Once again exposure duration may play a role 
in this difference.   
 For the most part, antioxidant therapy had little effect on any of the observed 
behaviors, which seemed to be driven largely by metal homeostasis.  Oxidative stress has 
been theorized to play a role in the sequelae of Mn neurotoxicity and neurodegenerative 
disorders (Sian et al., 1994; Schulz et al., 2000; Erikson et al., 2004; Weber et al., 2002).  
The lack of effect antioxidant therapy had on behavior suggests that oxidative stress plays 
a minimal role in Mn-induced behavioral alterations.  A more putative cause of Mn-
induced behavior changes (e.g. increased locomotor activity) may be neurochemical 
alterations in GABA or DA biology.    
  Overall, our results show that oral Mn exposure does indeed alter locomotor 
activity, as seen with increases in total distance traveled, and altered groom and sniff 
behaviors.  Though we did not examine neurotransmitter functionality directly, our 
results suggest some degree of underlying neurochemical alterations.  It is also apparent 
that antioxidant therapy with NAC and EGCG does not play a significat role in 
correcting alterations in stereotypic behaviors as a result of Mn accumulation. 
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CHAPTER V 
 
EPILOGUE 
 
 
 It is well established that manganese (Mn) and other divalent mtals play a role in 
neurological dysfunction.  The effect Mn has on neurobiology is multifaceted. Mn 
accumulation in the brain can disturb neurochemical homeostasis, as Mn i known to 
alter dopamine (DA),γ-aminobutyric acid (GABA), glutamate, and norepinephrine (NE) 
functionality (Fitsanakis et al., 2006; Anderson et al., 2009).  In the basalg ng ia these 
neurotransmitters work in concert to modulate motor control.  A disturbance in one can 
disregulate the entire system resulting in loss of fine motor cntrol, gait disturbances, and 
resting tremor, among other symptoms related to neurologic disorder.  Mn can disrupt 
neurotransmission by altering neurotransmitter receptor and transport proteins (Anderson 
et al., 2008; 2009), or by inhibiting the proper function of surrounding glial cells (Erikson 
et al., 2002b).  Glial cells, primarily astrocytes, help modulate the synaptic environment 
by clearing excess neurotransmitters along with extraneous metals ( .g. Mn accumulation 
in Mn neurotoxicity).  Astrocytes also support neuronal function by reccling amino 
acids (glutamate to glutamine) for ammonia clearance and neurotransmitter recycling, as 
well as providing substrate precursors for neuronal glutathione (GSH) synthesis (Dringen 
et al., 2000;).  Mn, however, can disturb these astrocytic functions leaving neurons 
vulnerable to excitotoxicity and oxidative stress.  
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 The purpose of this project was to further characterize the relationship between 
Mn accumulation in the brain and oxidative stress.  We examined the effect of oral Mn 
exposure on total GSH levels, mRNA levels of glutathione peroxidase (GPx) and 
catalase, the lipid peroxidation byproduct F2-Isoprostanes (F2-IsoPs), as well as altered 
stereotypic behaviors associated with Mn accumulation.  Additionally, we coupled N-
acetyl-cysteine (NAC) and (-)-epigallocatechin-3-gallate (EGCG) with Mn exposure to 
observe any protective benefits with antioxidant therapy.  We hypot esized:  1) If Mn 
exposure created oxidative stress (indirectly measured by altered GSH, GPx, catalase, 
and increased F2-IsoPs) NAC and EGCG therapy would attenuate those effects offering 
protection against Mn neurotoxicity. 2) If Mn-induced oxidative stres played a role in 
neurochemical changes leading to altered behavior, NAC and EGCG would help 
normalize movement and behavior abnormalities.  
 We found that while Mn did accumulate significantly in the caudate putamen 
(CP) and hippocampus (HC) of exposed rats, no significant signs of oxidative stress were 
present.  Only modest changes were observed in GSH levels suggesting minimal free 
radical generation.  No appreciable increase in F2-IsoP production and undisturbed 
catalase mRNA levels corroborate this finding.  Mn did, however, significantly increase 
GPx mRNA.  With respect to behavioral alterations, Mn significantly i creased total 
distance traveled suggesting underlying neurochemical alterations.  Decreased sniffing 
behavior in the Mn treatment group was also significant, and a trend toward significantly 
increased grooming was related to Mn exposure.  Again, NAC and EGCG had little effect 
on behavior alterations.  These data suggest that oral Mn exposure may not incur 
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significant oxidative stress or drastically alter neurotransmitter functionality; however, 
subtle neurochemical changes may result from this exposure paradigm.  
 The result of minimal Mn-induced oxidative stress was not a novel finding.  
Previous studies have shown increased, decreased, and no change of indirect mark rs of 
oxidative stress due to Mn exposure (Weber et al., 2002; Erikson et al., 2008; Taylor et 
al., 2006).  What is interesting is that we observed minimal changes in GSH, but 
increased GPx mRNA.  Increased GPx would, in theory, allow GSH to more efficiently 
quench peroxides.  This would suggest that an increase in reactive oxyg n species (ROS) 
were present, but we had little evidence to substantiate that claim.  It would have been 
interesting to measure oxidized GSH (GSSG) along with total GSH levels to obtain a 
better picture of GSH redox status.  Measuring GSSG may have pro ided insight as to 
why GPx levels were increased in the presence of no apparent oxidative stress.  
Alternatively, we could have directly measured ROS in tissue samples in addition to 
indirectly measuring F2-IsoP production.  Even though we did not see an effect of Mn on 
ROS generation, ROS can not be ruled out entirely in the etiology of Mn neurotoxicity.  
It just appears as though oral exposure to Mn may not cause severe enough damage to 
create substantial ROS.  Conversely, individuals exposed to airborne Mn may be at 
greater risk of oxidative injury.  In rats and monkeys, airborne exposure to Mn did result 
in altered biomarkers of oxidative stress (Taylor et al., 2006; Erikson et al., 2007, 2008).  
Perhaps the use of NAC and EGCG in airborne studies may be more indicative of their 
efficacy as antioxidant therapies. 
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 Oral Mn exposure did have an effect on behavioral patterns in this study.  Rats 
exposed to Mn experienced an increase in total distance traveled, which is indicative of 
neurochemical alterations (Flagel and Robinson, 2007).  We did not measure 
neurotransmitter levels directly in this study, but Mn exposure has been linked to altered 
DA, GABA, and NE biology (Fitsanakis et al., 2006; Anderson et al., 2009).  
Furthermore, these alterations have been associated with changes in locomotor and 
anxiety like behavior (Anderson et al., 2008, 2009).  We used sniffing and grooming 
behaviors, detected by Home Cage Scan (HCS) software, to represent changes in anxiety 
level.  A limitation to this is that there is no behavior universally regarded as an index for 
anxiety.  Solely monitoring changes in these behaviors may not be evid nce enough to 
categorize the rats as more or less anxious.  While using the HCS system may be 
convenient and is reportedly accurate (Steele et al., 2007), performing traditional 
behavior tests (e.g. open field test, Morris water maze, or radial arm maze) in conjunction 
with HCS may be useful to cross reference behavioral findings.  
 It is clear that Mn toxicity has an effect on neurochemical homeostasis; however 
it is difficult to say whether or not these alterations are d iven by oxidative stress.  
Additionally, route of Mn exposure may dictate the type and severity of damage.  Oral 
exposure may lead to subtle changes in neurobiology that manifest as cognitive or 
behavioral changes.  While airborne Mn may lead to increased oxidative s ress 
potentially causing neuronal damage and a subsequent neurodegenerative state.  Fu ure 
research should investigate the efficacy of antioxidant therapy in airborne Mn exposure.  
While oral Mn exposure studies may need to address the role of Mn in cellular signaling.  
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Mn exposure has been shown to alter protein kinase C (PKC) and intracellular calcium 
levels (Latchoumycandane et al., 2005), both of which are involved in cell signal 
cascades.  This could help elucidate mechanisms related to altered n urotransmitter 
homeostasis, neurotransmitter receptor and transporter changes, and modified gene 
expression profiles in the presence of Mn exposure.  Additionally, the relationship 
between Mn neurotoxicity and other divalent metals should be explored (e.g. copper) as a 
putative contributor to this neurological dysfunction.  Ultimately, data presented in the 
current study along with future research will help to develop treatm nt modalities for Mn 
neurotoxicity and other neurodegenerative diseases like Parkinson’s disease. 
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